Ozempic and other GLP-1 medications have done a lot for people with Type 2 diabetes. They help manage blood sugar, lower the risk of heart disease, and often bring down weight. What they do not seem to do, according to a new study, is change a person’s mental health, job prospects, or marriage.
Robert Kaestner, a research professor at the University of Chicago Harris School of Public Policy, and coauthor Cuiping Schiman published their findings as a working paper through the National Bureau of Economic Research. They looked at more than a decade of survey data, following adults with diabetes from 2012 to 2023. The goal was simple: do the physical benefits of these drugs spill over into daily life?
The answer, in short, is no.
Following Individuals Over Time
Kaestner and Schiman did not just compare people who took GLP-1 drugs with people who did not. That approach can miss the point, because the two groups often differ in ways that have nothing to do with the medication. Instead, they tracked the same individuals over time, watching whether their circumstances changed after starting treatment.
The team examined several measures of well-being:
- Depression symptoms
- Psychological distress
- Self-rated health
- Employment
- Marital status
Each measure is a different way of asking whether the drugs improve life beyond the body.
At first, the numbers showed some differences between users and non-users. People on GLP-1 drugs appeared to fare better on some of these measures than those who did not take the drugs. But when the researchers looked at how individual people changed over time, those gaps mostly vanished.
That pattern suggests the original gaps were not caused by the medications. They were caused by the kinds of people who chose to use them in the first place.
Consistent Across Time
The study found little evidence of meaningful change across all five measures, whether looking at people after roughly one year of GLP-1 use or following them over a longer two-year period. The results stayed consistent across both lengths of follow-up.
Kaestner was careful about what these findings mean. He stressed that the study does not prove GLP-1 drugs have no effects outside physical health. Some changes may simply be more subtle or harder to measure with the tools the study used.
“We measured outcomes like whether someone became employed or unemployed, whether they got married or divorced, and standard indicators of mental health,” he said. “Those are important measures, but they don’t necessarily capture changes in self-esteem, relationship quality, or other day-to-day experiences.”
What the Findings Do Not Change
The researchers made clear that their findings do not call the medical value of GLP-1 medications into question. For adults with diabetes, Kaestner said, the clearest measurable benefits remain those already shown in clinical research: improved blood sugar control, weight loss, and better physical health.
He also pointed out that the study only covered adults with diabetes. As GLP-1 medications become more widely used beyond diabetes and increasingly common for weight management, researchers will have more chances to study whether broader social effects appear in other groups or over longer periods.
“This is still a very new area of research,” he said. “As use continues to grow, understanding these broader consequences will become increasingly important for patients, clinicians, and policymakers alike.”
The Broader Picture
The question Kaestner and Schiman asked is now central to policy debates. Insurers and government programs are considering whether to broaden access to GLP-1 medications. Their medical benefits are already well documented. Whether the drugs also produce social or economic gains that could add to the argument for wider coverage is less clear.
The study’s design matters here. By following individuals over time, the researchers avoided the trap of comparing apples to oranges. They saw differences between users and non-users at a single point in time, but those differences mostly disappeared when they looked at how people changed within themselves.
That is a useful result, even if it is not the result many people expected. The popular image of GLP-1 drugs as a life-changer rests partly on the idea that weight loss and improved health translate into a better everything. This study does not support that idea.
There are limits to what the study can say. It only looked at adults with diabetes. It only measured a handful of outcomes. It did not track things like self-esteem, relationship quality, or day-to-day experiences, which Kaestner noted may be more subtle to capture.
Still, the pattern held across multiple measures and multiple lengths of follow-up. That consistency gives the findings weight.
The study does not settle the question of broader consequences. It narrows the search, though, by showing that the physical benefits of GLP-1 medications do not automatically extend into other parts of life.
The Verdict
The study’s honest reaction is skepticism. A major university study finds that while Ozempic improves physical health, it shows no measurable effect on mental health, employment, or relationships. That finding challenges the drug’s popular reputation as a life-changer.
The study does not prove Ozempic has no effects outside physical health. It simply found none that were large enough to measure with the tools available. Some changes may be more subtle or harder to capture.
The medical value of GLP-1 medications remains well established. Improved blood sugar control, weight loss, and better physical health are real and well documented. The broader picture, as Kaestner put it, is still a very new area of research.
As use of these drugs grows, the questions will keep coming.
Source material: “Ozempic can change your body. Can it change your life?,” ScienceDaily.
Get the Notebook.
The day's best stories and every fresh verdict, in plain English, in your inbox by seven. One email a day, no more.